Mithra Signs a License and Supply Agreement with Searchlight for Donesta in Canada
Shots:
- Mithra will receive a ~$1.58M milestone & is expected to receive an additional ~$16.42M in regulatory & sales milestones along with tiered royalties on annual net sales
- Searchlight is responsible for receiving & maintaining the regulatory approvals to market and distribute Donesta in the country. Both companies focus on providing innovative solutions to women by partnering on Myring, Estelle & Donesta
- Donesta is the next-generation medicine that contains Estetrol to treat menopause symptoms. Mithra highlighted the promising topline safety results from the P-III trial of Donesta in North America where results will support marketing authorization filings in the US in H2’23 and in Canada in 2024
Ref: Businesswire | Image: Mithra
Related News:- Mithra Signs License Agreement with Searchlight Pharma for Donesta in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
